In Wednesday’s session, Repligen Corporation (NASDAQ:RGEN) marked $240.40 per share, up from $237.38 in the previous session. While Repligen Corporation has overperformed by 1.27%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RGEN fell by -3.48%, with highs and lows ranging from $327.32 to $137.21, whereas the simple moving average jumped by 19.45% in the last 200 days.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Sponsored
On July 20, 2022, UBS started tracking Repligen Corporation (NASDAQ: RGEN) recommending Buy. A report published by Exane BNP Paribas on October 14, 2021, Initiated its previous ‘Outperform’ rating for RGEN. KeyBanc Capital Markets also rated RGEN shares as ‘Overweight’, setting a target price of $241 on the company’s shares in an initiating report dated November 10, 2020. H.C. Wainwright Reiterated the rating as Buy on August 24, 2020, but set its price target from $151 to $168. H.C. Wainwright resumed its ‘Buy’ rating for RGEN, as published in its report on June 30, 2020. H.C. Wainwright’s report from May 07, 2020 suggests a price prediction of $143 for RGEN shares, giving the stock a ‘Buy’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of Repligen Corporation (RGEN)
Further, the quarter-over-quarter increase in sales is 44.50%, showing a positive trend in the upcoming months.
Repligen Corporation’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of 8.50% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.70, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and RGEN has an average volume of 510.25K. On a monthly basis, the volatility of the stock is set at 4.84%, whereas on a weekly basis, it is put at 5.64%, with a gain of 16.86% over the past seven days. Furthermore, long-term investors anticipate a median target price of $236.89, showing decline from the present price of $240.40, which can serve as yet another indication of whether RGEN is worth investing in or should be passed over.
How Do You Analyze Repligen Corporation Shares?
Medical Instruments & Supplies giant Repligen Corporation (RGEN) is based in the USA and is one of the largest companies in the market. When comparing Repligen Corporation shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 95.25, there is a growth in quarterly earnings of 54.20%.
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.70%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 89.20% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in RGEN shares?
The recent increase in stakes in RGEN appears to be a result of several institutional investors and hedge funds increasing their positions. The Vanguard Group, Inc.’s position in RGEN has decreased by -0.33% in the first quarter. The company now owns 4,819,672 shares of the stock, with a value of $782.71 million, following the sale of -16,032 additional shares during the last quarter. BlackRock Fund Advisors made another increased to its shares in RGEN during the first quarter, upping its stake by 1.51%. During the last quarter, the company picked up 67,932 additional shares for a total stake of worth $741.25 million, bringing number of shares owned by the company to 4,564,353.
During the first quarter, T. Rowe Price Associates, Inc. added a 733,449 position in RGEN. Invesco Advisers, Inc. purchased an additional 88655.0 shares in the last quarter, increasing its holdings by 5.88%, now holding 1.6 million shares worth $259.43 million. At the end of the first quarter, Brown Capital Management LLC increased its RGEN holdings by 44.02% and now holds 1.45 million RGEN shares valued at $236.25 million with the added 0.44 million shares during the period. RGEN shares are owned by institutional investors to the tune of 89.20% at present.
